Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00755638 | A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers | PHASE1 | COMPLETED | 48 | — | — | Sep 1, 2008 | Jul 1, 2009 | Jul 14, 2009 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| single | EXPERIMENTAL | 8 subjects (6 active and 2 placebo) |
| Name | Type | Description |
|---|---|---|
| ACE-031 | BIOLOGICAL | single subcutaneous dose of ACE-031 |
Key Inclusion Criteria: 1. Subject is a postmenopausal woman, 45-75 years old (inclusive) 2. Subject has a body mass index (BMI) of \> 18.5 to \< 30 3. Subject must give written informed consent Key Exclusion Criteria: 1. Subject has a history of malignancy. However, a subject with a history of e...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Abbott Laboratories | ABT | 1 | — | Undisclosed |
| CytoSorbents Corporation | CTSO | 1 | — | Undisclosed |